Program
elegrobart
Also written as “VRDN-003” and “ZL-1109 (VRDN-003)”.
Its studies are mostly in Graves Ophthalmopathy, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viridian Therapeutics | 43 open or running | phase 3since Oct 1, 2024 | Oct 1, 2024 | none ahead |
| Zai Lab | 11 open or running | phase 3since Oct 1, 2025 | Oct 1, 2025 | Mar 14, 2027phase 3 · NCT07211776 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 1, 2024First studies: 2 phase 3 studies in Graves OphthalmopathyNew to Viridian TherapeuticsViridian Therapeutics · NCT06625411, NCT06625398
- Jan 27, 2025Phase 3 study in Graves OphthalmopathyViridian Therapeutics · NCT06812325 · 320 enrolled · United States, France, Germany and more
- Aug 7, 2025Phase 3 study in Graves OphthalmopathyViridian Therapeutics · NCT07155668 · 87 enrolled · United States
- Oct 1, 2025Zai Lab's first study: phase 3 study in Graves OphthalmopathyNew to Zai LabZai Lab · NCT07211776 · 108 enrolled · China
Ahead
- Mar 14, 2027Primary completion: phase 3 study in Graves OphthalmopathyZai Lab · NCT07211776
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07211776Graves Ophthalmopathy · China | 3 | Active, not recruiting | Zai Lab | Mar 14, 2027 | 108 |
| NCT07155668Graves Ophthalmopathy · United States | 3 | Completed | Viridian Therapeutics | May 28, 2026 | 87 |
| NCT06812325Graves Ophthalmopathy · United States, France, Germany and more | 3 | Active, not recruiting | Viridian Therapeutics | Apr 22, 2026 | 320 |
| NCT06625411Graves Ophthalmopathy · United States, Germany, Hungary and more | 3 | Active, not recruiting | Viridian Therapeutics | Feb 12, 2026 | 132 |
| NCT06625398Graves Ophthalmopathy · United States, Germany, Hungary and more | 3 | Active, not recruiting | Viridian Therapeutics | Mar 4, 2026 | 204 |
How it is read
Names in the registry
- “VRDN-003”, 4 entries
- “ZL-1109 (VRDN-003)”, 1 entry
Conditions, from the studies’ own filings
- Graves Ophthalmopathy, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.